Edgewise Therapeutics Announces Plans for 2025
Edgewise Therapeutics has announced its 2025 plans for Duchenne muscular dystrophy. The company said in a statement that it will prioritize Sevasemten.
Sevasemten is an...
Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics
Dyne Therapeutics announced positive clinical data for its therapies DYNE-101 and DYNE-251 during an investor event on January 10, 2025. DYNE-101 for myotonic dystrophy...
Avidity Biosciences Prepares for Three Rare Muscle Disease Programs’ 2025 BLA Submission and Commercialization
A biopharmaceutical firm dedicated to developing a novel class of RNA treatments known as Antibody Oligonucleotide Conjugates (AOCsTM), Avidity Biosciences, Inc., today reported its...
Percheron Disappointed in Avicursen (ATL1102) Study For Duchenne (DMD)
Percheron Therapeutics has announced that it will investigate avicursen (ATL1102) in other indications besides Duchenne muscular dystrophy (DMD) following disappointing Phase IIb results last...
Santhera Enters into Supply and Distribution Agreement for AGAMREE (Vamorolone) with Clinigen Group
Santhera Pharmaceuticals announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where...